Iodine-125 brachytherapy linked to longer survival in HCC with hepatic vein tumor thrombus
In 76 patients with HCC and hepatic vein tumor thrombus, adding iodine-125 brachytherapy was associated with median survival of 22.1 versus 14.0 months.
In 76 patients with HCC and hepatic vein tumor thrombus, adding iodine-125 brachytherapy was associated with median survival of 22.1 versus 14.0 months.
In 45 patients with hepatocellular carcinoma, MR-guided SBRT achieved 90% two-year local control without reported grade ≥3 acute toxicity.
Evidence is strongest in hepatocellular carcinoma, where higher tumor doses correlate with pathological necrosis, while non-HCC dose thresholds remain uncertain.
A comprehensive review integrates randomized HCC radiotherapy evidence with practical recommendations for liver-function assessment, dose constraints, motion management and high-risk treatment.
A simplified density-assignment workflow achieved 99.2% gamma agreement in retrospective liver SABR plans and 98.8% in the first five trial patients.
Three representative liver cases illustrate breath-hold IMPT, compression-based proton SBRT and spatially fractionated proton therapy with detailed planning and QA workflows.
Age ≥75 did not independently predict outcomes after proton therapy for HCC, while CCI ≥3 was associated with more than threefold higher mortality.
IPTW-weighted response was 71.1% versus 37.6%, with median survival 23.0 versus 15.6 months after adding SBRT.
Twelve VMAT lattice courses produced 65% median tumor shrinkage and no local progression during short follow-up in bulky hepatocellular carcinoma.
DCAF4 activated NRF2-dependent antioxidant defence and protected hepatocellular carcinoma against iodine-125 brachytherapy in preclinical models.
PVC was detected in 37 of 72 HCC tumors and was associated with poorer response and progression-free survival after SBRT, immunotherapy, and bevacizumab.
After stereotactic body radiation therapy for hepatocellular carcinoma, magnetic resonance response evolved over months, making early enhancement alone unreliable.
Respiratory gating more than halved cranio-caudal motion, while motion-related target-dose deviations largely diminished after accumulation across more than three fractions.